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Abstract
The immunogenicity of biotherapeutics can bottleneck development pipelines and poses a barrier to widespread clinical
application. As a result, there is a growing need for improved deimmunization technologies. We have recently described
algorithms that simultaneously optimize proteins for both reduced T cell epitope content and high-level function. In silico
analysis of this dual objective design space reveals that there is no single global optimum with respect to protein
deimmunization. Instead, mutagenic epitope deletion yields a spectrum of designs that exhibit tradeoffs between
immunogenic potential and molecular function. The leading edge of this design space is the Pareto frontier, i.e. the
undominated variants for which no other single design exhibits better performance in both criteria. Here, the Pareto frontier
of a therapeutic enzyme has been designed, constructed, and evaluated experimentally. Various measures of protein
performance were found to map a functional sequence space that correlated well with computational predictions. These
results represent the first systematic and rigorous assessment of the functional penalty that must be paid for pursuing
progressively more deimmunized biotherapeutic candidates. Given this capacity to rapidly assess and design for tradeoffs
between protein immunogenicity and functionality, these algorithms may prove useful in augmenting, accelerating, and
de-risking experimental deimmunization efforts.
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Introduction
Therapeutic proteins are revolutionizing disease therapy across
a broad range of indications and illnesses, and biotherapeutic sales
are an increasingly important part of the pharmaceuticals market
[1,2]. However, these powerful drugs suffer from their own
limitations, which, if addressed, could accelerate the pace of
biotherapeutic development and approval. A relatively unique risk
factor for protein therapeutics is their inherent potential to induce
anti-drug immune responses in human patients [3,4,5]. These
undesirable immune reactions can compromise drug efficacy or
cause more serious adverse events [6,7].
In a healthy human immune system, all extracellular proteins
are sampled by antigen presenting cells (APCs). Once internalized
by APCs, a protein is cleaved into small peptide fragments,
putative immunogenic segments are loaded into the groove of class
II major histocompatibility complex proteins (MHC II), and the
complexes are trafficked to the APC surface. True immunogenic
peptides, termed T cell epitopes, facilitate the formation of ternary
MHC II-peptide-T cell receptor complexes with surface receptors
of cognate CD4+ T cells [8]. This critical molecular recognition
event initiates a signaling cascade that drives stimulation of helper
T cells, maturation of B cells, and ultimately production of
circulating antibodies that bind to and clear the foreign
therapeutic protein. Detailed knowledge of this process enables
protein deimmunization via mutation of key residues in immuno-
genic epitopes, a methodology commonly known as T cell epitope
deletion.
There exist in the literature numerous examples of successful T
cell epitope deletion projects. To date, the majority of these efforts
have relied on time, labor, and resource intensive experimental
strategies. Experimentally driven approaches entail dividing the
target protein’s primary sequence into a large panel of overlapping
peptides, synthesizing those peptides, and using them for
exhaustive epitope mapping with human peripheral blood
mononuclear cells and/or purified human MHC II proteins
[9,10,11,12,13,14]. To circumvent the considerable effort and
expense required for experimental epitope mapping, a wide range
of epitope prediction tools may be accessed
[15,16,17,18,19,20,21,22,23]. In some recent cases, such tools
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have been leveraged to good effect in deimmunizing therapeutic
candidates [24,25].
Identification and mapping of T cell epitopes is a relatively
mature field, but selection of mutations that simultaneously delete
epitopes and maintain protein function remains a challenging task.
Experimentally driven deimmunization typically relies on alanine
scanning or similar empirical strategies to select epitope deleting
mutations. While Cantor et al. employed epitope prediction to
rapidly identify immunogenic regions of asparaginase, their
selection of deimmunizing yet function-preserving mutations
required construction of large combinatorial protein libraries
and implementation of a sophisticated ultra-high throughput
screen [24]. As an alternative to the above methods, bioinfor-
matics tools are increasingly used to filter prospective deimmuniz-
ing mutations for those least likely to disrupt protein structure and
function [12,26], however these in silico analyses of a mutation’s
structural and functional consequences have historically been
applied post hoc. Any such sequential application of computational
tools fails to consider the combined effects of all mutations on
immunogenicity and function, thereby precluding a global
approach to protein deimmunization. Thus, while T cell epitope
deletion is a well validated methodology, the success, efficiency,
and general utility of the approach would be enhanced by bringing
to bear more advanced protein engineering and design technol-
ogies.
The next generation of protein deimmunization tools have
seamlessly integrated immunoinformatic epitope prediction with
in silico analysis of the functional consequences associated with
prospective deimmunizing mutations [27,28,29,30]. By packaging
both design objectives in a single optimization algorithm, these
technologies enable global protein design and deimmunization on
a highly compressed time scale. The first two iterations of these
novel algorithms, Dynamic Programming for Deimmunizing
Proteins (DP2) and Integer Programming for Immunogenic
Proteins (IP2), have undergone preliminary experimental valida-
tion with Enterobacter cloacae P99 Beta-lactamase (P99bL)
[25,31], a biotherapeutic that has been deimmunized previously
using conventional experimentally-driven techniques [9]. Here we
deimmunize the P99bL target using a more advanced extension of
IP2, embodied in the protein design algorithm ‘‘Protein Engineer-
ing Pareto Frontier’’ (PEPFR) [32]. Whereas IP2 samples a subset of
the designs that optimally balance the immunogenicity and
functionality objectives, PEPFR generates the entire set of Pareto
optimal variants, i.e. all enzymes whose predicted immunogenicity
and functionality are not simultaneously dominated by any other
single design. Eighteen of these Pareto optimal variants have been
produced and subjected to a rigorous experimental analysis of key
performance parameters. This combined computational and
experimental analysis of increasingly aggressive plans has provided
new insights into the inherent tradeoffs linking the target enzyme’s
sequence, function, and immunogenic potential. As a whole, this
work outlines a design-based approach to functional deimmuniza-
tion of biotherapeutic candidates.
Results
Computational Design
Whereas previous computationally-driven deimmunization of
P99bL had targeted eight common MHC II alleles [25,31], here
we optimized against only four alleles (DRB1*0101, 0401, 0701,
and 1501) for which MHC II-peptide binding experiments had
been fully optimized [33]. Analysis with the ProPred epitope
prediction tool [20] revealed that putative immunogenic peptides
were broadly distributed throughout the sequence, with several
discrete regions exhibiting numerous overlapping and promiscu-
ous epitopes, e.g. proximal to residues 14, 105, 210, 235, and 334
(Fig. 1). While our prior P99bL deimmunization efforts had
focused on validation of our protein optimization algorithms, the
objective of the current study was a systematic analysis of the
sequence-function-immunoreactivity tradeoffs that are inherent to
the deimmunization process.
In pursuit of this goal, we applied the PEPFR protein design
algorithm [32] to optimize the two objective functions derived
from the IP2 deimmunization formulation [28]: a sequence score
(Sseq, materials and methods equation 1), capturing the predicted
effects of mutations on protein function, and an epitope score (Sepi,
materials and methods equation 2), capturing the predicted effects
of mutations on protein immunogenicity. Both scores are defined
such that lower is better (less perturbation to function and reduced
immunogenicity, respectively). PEPFR identifies the ‘‘Pareto fron-
tier’’ of the deimmunized design space, comprised of those designs
whose sequence and epitope scores are not simultaneously
dominated by any other variant (i.e., those designs making the
best tradeoffs between the scores). Separate PEPFR runs were
performed to identify designs at mutational loads ranging from 1
to 8.
The resulting output was a panel of 18 P99bL designs that
exhibited a range of mutational loads and extents of epitope
disruption. A plot of Sseq vs. Sepi for the 18 protein plans enabled
visualization of the objective functions’ competing nature (Fig. 2).
The overarching goal was reduction of P99bL epitope score via
mutagenic deletion of predicted epitopes; however each deimmu-
nizing mutation incurs an Sseq penalty. Any increase above the
wild type Sseq reflects a putative risk of reduced protein stability
and/or function, and therefore mutagenic deimmunization must
carefully balance the opposing objective functions. The Pareto
frontier analysis (Fig. 2) highlights the relative tradeoffs between
predictions of epitope content and biological activity, but the
Author Summary
Protein therapeutics have created a revolution in disease
therapy, providing improved outcomes for prevalent
illnesses and conditions while at the same time yielding
treatments for diseases that were previously intractable.
However, this powerful class of drugs is subject to their
own unique challenges and risk factors. In particular, the
biological origins of therapeutic proteins predispose them
towards eliciting a detrimental immune response from the
patient’s own body. Therefore, fully capitalizing on the
medicinal reservoir of natural and engineered proteins will
require efficient, effective, and broadly applicable deim-
munization technologies. We have developed deimmuni-
zation algorithms that simultaneously optimize therapeu-
tic candidates for both low immunogenicity and high-level
activity and stability. Here, we combine computational
modeling and experimental analysis to show that the
process of protein deimmunization manifests inherent
tradeoffs between immunogenic potential and biomolec-
ular function. Our experimental results demonstrate that
dual objective optimization allows us to assess and design
for these tradeoffs, thereby enabling facile construction of
deimmunized variants that span a broad range of
immunogenicity and functionality performance parame-
ters. Thus, we can rapidly map the design space for
deimmunized drug candidates, and we can use this
information to guide selection of engineered proteins that
are most likely to meet performance benchmarks for a
given clinical application.
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Fig. 1. Epitope map of P99bL. The P99bL sequence was analyzed using ProPred set to a 5% threshold. Every nonamer peptide was classified as a
binder or non-binder of alleles DRB1*0101, 0401, 0701, and 1501. The number of alleles that bind each nonamer peptide (y-axis) is indicated by a bar
at the starting position of the peptide (x-axis). The positions of engineered mutations from the deimmunized enzymes are indicated with blue arrows
and residue numbers.
doi:10.1371/journal.pcbi.1003988.g001
Fig. 2. Pareto frontier of the P99bL deimmunized design space. The computed Sseq design parameter is plotted vs. the computed Sepi design
parameter for 19 unique enzyme plans. Sseq derives from a statistical sequence potential, and is analogous to an energy function such that lower
values are better. Sepi is the total predicted epitope count for each protein. Pareto optimal designs, i.e. those for which no other single design has
both better epitope and sequence scores, are indicated with blue circular markers. In orange are three 4-mutation designs that are Pareto optimal at
their specific mutational load but are outperformed by designs at higher mutational loads. Wild type P99bL is indicated with a red square. Mutational
loads are indicated adjacent to their cognate markers. For three representative proteins, the epitope content has been mapped onto the P99bL
peptide backbone (PDB ID 1XX2A). Dense regions of overlapping epitopes are shown as thick red tubes, and lower densities are indicated with
incrementally thinner tubes colored in a gradient red-orange-yellow-green-blue. Epitope free regions are thin grey tubes. 3-dimensional epitope
maps are shown for wild type P99bL, design 4O, and design 8Z.
doi:10.1371/journal.pcbi.1003988.g002
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practical relationship between these mathematical functions is an
unknown quantity. Thus, experimental analysis is ultimately
required to understand the magnitude of biological activity that
is sacrificed per unit immunogenicity.
Incrementally enhanced deimmunization, moving from right to
left on the Pareto curve (Fig. 2), was realized by three comple-
mentary mechanisms. First, increasing mutational loads allowed
for simultaneous disruption of multiple, distributed epitope
clusters. Compare, for example, design 1I, which targets a single
epitope with one mutation, to design 8Z, which targets seven
distinct immunogenic regions with eight mutations (Table 1).
Second, in some instances accrued mutations were combined in
close proximity to better target one particularly immunogenic
region. For example, designs 4M through 7S as well as plan 8U
encoded the R105S mutation, which was predicted to disrupt
three of seven epitopes in a dense cluster centered on position 105
(Fig. 3). The more ambitious designs 8V through 8Z deleted six of
these same seven epitopes with the combined G103D+R105S
double mutation. The mutational combinations M235Q+V243L
and Q333D+I334L were likewise predicted to yield enhanced
epitope deletion relative to their single mutation counterparts
(Fig. 3). In parallel to escalating mutational loads, a third
mechanism for improved epitope deletion was the use of
increasingly aggressive individual mutations. In particular, muta-
tion N14R was associated with three designs possessing moderate
sequence scores (4N, 5R, and 8V; Sseq range of 17.1 to 41.4;
Table 1), but it deleted only three of six epitopes in the dense
cluster centered on residue 14 (Fig. 3). Mutation A13E, employed
by six designs having a Sseq range of 25.3 to 107.6, disrupted five of
the six epitopes in this cluster. Finally, A13D deleted all six
predicted epitopes, but this aggressive substitution contributed to
particularly poor overall sequence scores (Sseq = 98.8 and 144.8 for
designs 4P and 8Z, respectively). In aggregate, incremental
increases in mutational load and mutational stringency produced
a systematic series of deimmunized designs ranging from the wild
type Sepi = 60 to that of variant 8Z (Sepi = 32), in which almost half
of the predicted epitopes were targeted for disruption.
Cloning, Expression, and Purification
Engineered gene constructs were assembled by recursive PCR
from overlapping synthetic oligonucleotides, and each gene was
modified with a 59-coding sequence for the OmpA leader peptide
and a 39-coding sequence for a C-terminal hexa-histidine tag.
Genes were cloned behind the strong T7 promoter of vector
pET26b, and proteins were expressed in the E. coli host
BL21(DE3) [F– ompT hsdSB (rB
- mB
-) gal dcm (DE3)]. Recombi-
nant enzymes were released from the periplasm by osmotic shock
and subsequently purified to.95% by immobilized metal affinity
chromatography. Yields were 1–30 mg/liter of cell culture,
depending on the enzyme variant.
Thermostability Analysis
The relative structural stabilities of the eighteen engineered
enzymes were assessed as apparent melting temperatures (Tm),
quantified by differential scanning fluorimetry [34]. The Tm’s of
the eighteen variants ranged from 47.09–56.27uC, or 83–99% of
Fig. 3. Detailed view of T cell epitopes targeted for disruption. The four MHC II alleles of interest are shown on the y-axis, and peptide sub-
sequences of P99bL are shown on the x-axis. Deimmunizing mutations are specified above each graphic, and sites of mutation are indicated by
asterisks on the x-axis. The precise positions of predicted T cell epitopes in wild type P99bL are indicated by solid black lines. Predicted epitopes in
the specified engineered sequence are indicated with hatched orange lines. Overlapping black and orange lines are predicted epitopes not deleted
by the specified mutation or mutations.
doi:10.1371/journal.pcbi.1003988.g003
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the wild-type value (56.61uC) (Table 1). While the observed 9.5uC
range in Tm should not be interpreted as insubstantial, it bears
noting that none of the engineered variants exhibited significant
unfolding at 37uC (S1 Fig.), which is the temperature of ultimate
therapeutic relevance.
The incremental manner in which the design series progres-
sively targeted epitopes resulted in extensive mutational overlap
between adjacent designs, and insights regarding the destabilizing
effects of specific substitutions were obtained by deconvoluting the
mutational composition of various constructs. Consider for
example the adjacent series 1J, 2K, and 4L. Design 1J encoded
only M235Q, which resulted in a negligible 0.64uC reduction in
Tm (Table 1). In contrast design 2K, which encoded both M235Q
and R210H, exhibited a 2.83uC drop in Tm, indicating that
R210H has a significant destabilizing effect, either by itself or in
the context of M235Q. The next variant, 4L, revealed that neither
V25I nor T342K were destabilizing substitutions, as 4L differed
from 2K by only these mutations yet exhibited an equivalent Tm.
The permissible natures of V25I and T342K were further
corroborated by comparison of Tm’s for 5Q vs. 4M and 1I vs.
WT, which differed by the respective single mutations and again
possessed essentially the same Tm values.
Separately, the data indicated that substitutions N14R and
A13E were interchangeable with respect to structural integrity. In
particular, the 4-mutation designs 4N and 4O differed only by
N14R and A13E, respectively, and the 8-mutation variants 8V
and 8W exhibited the same distinguishing feature. In both cases,
the two alternative substitutions yielded essentially equivalent Tm
values (49.47<49.74uC and 50.01<50.25uC, respectively). More-
over, there was evidence that these N-terminal mutations did not
further compromise designs already exhibiting moderately de-
creased stability. For example, 5R differed from 4M by the simple
addition of N14R, yet both enzymes showed similar stability
(Tm = 50.15 and 49.95uC, respectively).
The most striking observation, however, was the clear
bifurcation in Tm values between designs that encoded R105S
and those that did not. Without exception, plans bearing R105S
possessed Tm’s below 52uC (average Tm = 49.53uC), while variants
bearing wild type R105 uniformly exhibited Tm’s above 53uC
(average Tm = 55.09uC). This suggested that R105S was the single
most destabilizing mutation from the study, and separate
experiments on the R105S point mutant showed that this single
mutation substantially reduced protein stability (Tm = 52.64uC, S1
Table). It seems likely that this effect stems from the fact that R105
resides in the center of a pocket defined in part by D86, D87,
D108, and E300 (S2 Fig.). Presumably, R105 electrostatically
stabilizes the adjacent acidic residues, and removal of this positive
charge by the R105S mutation renders the protein less stable.
Interestingly, while the isolated R105S mutation caused a
reduction in thermostability, it manifested no substantial effect
on catalytic activity (S1 Table), and it provided for a net reduction
in peptide interaction with human MHC II proteins (see results
below). Thus, the unfavorable consequences of R105S appeared to
be confined to structural stability.
Finally, it should be noted that the sequence potential was
intended, in part, to quantify the likelihood that mutations or
combinations of mutations would maintain P99bL structural
integrity. A plot of Sseq vs. apparent Tm yielded the expected
inverse relationship, and a linear regression showed that the
correlation was highly significant (non-zero slope, P = 0.0019)
(Fig. 4A). While the sequence potential was not an accurate
predictor of individual Tm values (linear R
2 = 0.44), from a global
perspective it did effectively capture this aspect of experimental
performance.
Kinetic Analysis
A second goal of the sequence potential was to select mutations
least likely to disrupt P99bL activity. To assess mutational effects
on molecular function, Michaelis-Menten kinetic parameters were
quantified using the beta lactam substrate nitrocefin (Table 1).
Linear regression of Sseq vs. turnover number (kcat) or catalytic
efficiency (kcat/Km) revealed a highly significant inverse correla-
tion (non-zero slope, P = 0.0098 and 0.0005, respectively), whereas
there was not a strong correlation with Km (Fig. 4B, C, D). Similar
to the relationship with Tm, the sequence potential could not be
used to predict catalytic proficiency for individual enzymes, but it
did accurately reflect the overall trends for measured reaction rates
and catalytic efficiency.
The kcat values for individual designs ranged from 65–206%
that of wild type P99bL (average over all variants = 114%).
Notably, 11 of 18 variants exhibited faster than wild type
maximum reaction velocities. However, the majority of variants
(15/18) also experienced an increase in Km, and as a result the
average kcat/Km for all variants was 88% that of wild type
(ranging from 56–121%). In general, wild type or better reaction
rates and catalytic efficiencies were maintained up through the
two least aggressive 8-mutation plans, 8T and 8U. The two
variants with the highest overall kcat/Km values were designs 5Q
and 5R (109% and 121% of wild type, respectively), and in both
cases these enhanced efficiencies were driven exclusively by
substantial increases in the kcat parameter (206% and 164% wild
type, respectively). Together, these observations highlight the fact
that the wild type sequence does not represent a global optimum
with respect to catalytic conversion of nitrocefin. The functional
deimmunization process identified numerous performance en-
hanced variants, and the high activity observed across the full
spectrum of mutational loads underscores the practical utility of
the statistical sequence potential. Indeed, even the five most
aggressive 8-mutation designs (8V through 8Z) proved to be
highly active enzymes, with kcat and kcat/Km values that averaged
77% and 71%, respectively, of wild type. The single most
deimmunized variant, 8Z, maintained well above 50% wild type
rate acceleration and efficiency. Thus, all 18 deimmunized
enzymes exhibited activity comparable to naturally evolved
biocatalysts.
Peptide Binding
The immunoreactivity of various constructs was assessed by
measuring the MHC II binding affinity of their corresponding
peptide fragments. These competition immunoassays are a widely
recognized metric for assessing immunogenic potential and
validating computational predictions [22,25,33,35,36,37,38,39].
Synthetic fragments of wild type P99bL were designed so as to
encompass each of the epitopes targeted by the deimmunization
algorithm, and corresponding variant peptides were synthesized to
represent the deimmunized designs (S2 Table). The affinity of
each peptide for human MHC II molecules DRB1*0101, 0401,
0701, and 1501 was measured by competition with known peptide
immunogens for each allele. A quantitative comparison of wild
type versus variant MHC II binding affinity was used as a proxy
measure for the success of epitope deletion (Fig. 5). Peptide
affinities are reported as IC50 values, and putative epitopes were
classified as strong (IC50,1 mM), moderate (1 mM#IC50,
10 mM), weak (10 mM#IC50,100 mM), or non-binders (IC50$
100 mM).
High affinity interaction between peptide antigens and class II
MHC is a key determinant of subsequent T cell immunogenicity
[40,41,42], and a total of four wild type P99bL peptides were
found to possess sub-micromolar IC50’s for one or more of the
Pareto Optimal Deimmunization of a Biotherapeutic
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tested alleles. The wild type A13+N14 peptide was a high affinity
binder of DRB1*0701 (IC50 = 800 nM), and both A13D and
A13E successfully converted this to a weak binding interaction
with N14R yielding a moderate binding interaction (Fig. 6). As
found in prior studies [25], wild type peptide L149 was bound by
all four alleles, and here it was a particularly strong binder of 1501
(IC50 = 300 nM). The L149Q mutation reduced 1501 affinity by
40-fold, converting this strong binding interaction to a weak
interaction. Wild type peptide I262 also bound all four alleles, and
it possessed sub-micromolar affinity for both 0401 and 1501. The
I262V mutation yielded a 6-fold reduction in 1501 affinity,
thereby converting a strong binder to a moderate binder. In
contrast, I262V did not substantially alter affinity for allele 0401,
although this outcome was predicted during the design process
(Fig. 3). The only other high affinity binding of a wild type peptide
was 0101 binding of I48, which, contrary to predictions, was
unaffected by the I48V mutation.
A total of 29 peptides, 11 wild type and 18 engineered, were
analyzed to produce 116 affinity measurements. Of the 72 pairs of
wild type and cognate deimmunized affinities (Fig. 5), there were
16 cases in which the designed mutation reduced MHC II affinity
by more than an order of magnitude. There were an additional 11
instances wherein the designed mutation reduced affinity by 5- to
10-fold, and 10 examples of more modest 2- to 5-fold reductions.
In aggregate the engineered mutations showed a 37.5% success
rate in reducing MHC II binding by 5-fold or more. In contrast,
there were only nine total instances in which the designed
mutation enhanced MHC II affinity by any measurable degree. In
five of those cases, the increase was a modest 2- to 5-fold, and
there were no quantified examples of 10-fold or greater increases
in affinity.
To correlate the experimentally measured MHC II affinities
with the algorithm’s binary prediction of peptide binding/non-
binding, a threshold value for experimental ‘‘binding’’ was
arbitrarily selected. So as to maintain consistency with our prior
work on P99bL, we set the cutoff for experimental binders at an
IC50,100 mM, i.e. counting all strong, moderate, and weak
binders as defined above. Given this experimental threshold and a
ProPred prediction threshold of 5%, the protein design process
yielded a 65% positive prediction rate for binders across all four
alleles (Fig. 6). Predictions were most accurate for DRB1*0401
(76%) and least accurate for allele 0701 (59%). Overall, we
observed a 13% false positive rate and a 22% false negative rate,
similar to those we have reported previously [25,31]. Comparable
analyses using the newer IEDB consensus [22] and NNAlign [34]
prediction methods revealed that, in this instance, no single
predictor exhibited dominant accuracy across all four alleles (S3,
S4 and S5 Tables). In particular, the ProPred predictor was
comparable to the others for the peptides assessed here. As a whole
the results show that the IP2 deimmunization formulation,
implemented through the PEPFR protein design algorithm and
using the ProPred epitope predictor, proved to be proficient at
identifying high affinity MHC-binding peptides and selecting
corresponding disruptive mutations.
To enable comparison of whole protein immunoreactivity,
MHC II binding data for individual peptides was integrated across
the full length of each enzyme design. For each protein, a
categorical immunoreactivity score was obtained by summing the
number of strong, moderate, and weak MHC binders across the
protein’s component peptides (11 peptides N 4 MHC alleles = 44
possible interactions). Consistent with the predicted Sseq epitope
parameter (Table 1), the design series showed a general trend of
Fig. 4. Correlations between computational design parameters and experimentally measured performance metrics. A Sseq vs. Tm. B
Sseq vs. Km. C S
seq vs. kcat. D S
seq vs. kcat/Km. E Global Quantitative Immunoreactivity vs. S
epi. (former as defined in equation 4). Pareto optimal enzymes
are shown as blue circular markers, sub-optimal 4-mutation variants are shown as orange circular markers, and wild type P99bL is shown as a red
square. Linear regressions are shown along with R2 values, and an F test was used to determine statistical significance for non-zero slopes (P values
are provided).
doi:10.1371/journal.pcbi.1003988.g004
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Fig. 5. Peptide binding affinities for human MHC II proteins. IC50 values are plotted as cognate wild type and variant pairs, where lower IC50
values correspond to higher affinity binding with human MHC II. The slope of the connecting lines are a relative measure of deimmunizing efficacy,
where larger positive slopes indicate a greater fold decrease in affinity relative to wild type. Lines with negative slopes indicate a mutation that
enhanced MHC II binding. Shading indicates binding strength by category: strong (IC50,1 mM, dark grey), moderate (1 mM#IC50,10 mM, medium
grey), weak (10 mM#IC50,100 mM, light grey), or non-binding (IC50 $100 mM, white).
doi:10.1371/journal.pcbi.1003988.g005
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decreasing experimental immunoreactivity moving from variant 1I
to 8Z (Fig. 7). Of the 18 engineered designs, 11 had a net deletion
of one or more high affinity interactions, 17 deleted one or more
moderate affinity interactions, and 16 deleted one or more weak
interactions. Importantly, none of the engineered enzymes suffered
a net increase in total experimental epitopes. In only one case was
a design found to have a net addition of epitopes in any single
binding category. Namely, 4P possessed one additional weak
binder, but at the same time it deleted four moderate and two
strong binders, the latter two being most prone to drive a T cell
Fig. 6. Epitope predictions, measured IC50 values, and correlations by individual peptide. For each MHC allele, the number of predicted
epitopes within a given synthetic peptide is shown on the left, and the measured IC50 values are shown on the right. Peptides were categorized as
strong (IC50,1 mM, red), moderate (1 mM#IC50,10 mM, orange), weak (10 mM#IC50,100 mM, yellow), or non-binding (IC50 $100 mM, white).
Positive correlations between epitope prediction and experimental measurements (binding cutoff at 100 mM) are highlighted in blue on the left.
doi:10.1371/journal.pcbi.1003988.g006
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mediated immune response [40]. Indeed, with respect to deleting
moderate and strong binders, design 4P was bested only by 8Z.
The latter was the single most aggressive design, and it was in fact
found to have the lowest categorical immunoreactivity. Specifi-
cally, 8Z yielded a net deletion of three strong binders, four
moderate binders, and one weak binder, thereby eliminating a full
quarter of all experimentally identified MHC II binders.
Considering only the higher affinity peptides (IC50,10 mM), 8Z
benefitted from a 39% reduction in epitope content, similar to the
47% reduction predicted by the deimmunization algorithm. Thus,
prediction of epitope disruption was borne out in the overall
experimental analysis.
As a second measure of whole-protein immunogenic potential, a
global quantitative immunoreactivity value was calculated by
averaging the numerical IC50’s for each enzyme’s component
peptides. Importantly, the dynamic range for our MHC II binding
assay is 10 nM to 250 mM, and many of the binding affinities,
particularly for engineered peptides, were found to be too weak for
precise quantitation (values.250 mM, Fig. 6). Because these non-
binding peptides are key indicators of reduced immunoreactivity,
it was critical that they be factored into the quantitative, whole-
protein score. To do so, we employed equation 4 (see materials
and methods). Each enzyme’s global immunoreactivity, normal-
ized to 100% for wild type P99bL, is reported in Table 1. Similar
to the categorical analysis, there was a general trend towards
decreased global immunoreactivity with increasing mutational
load and aggressiveness. On this normalized scale, designs 8T and
8U are the most immunotolerant variants, both exhibiting a 65%
reduction relative to wild type P99bL immunoreactivity. The most
extensively engineered design, 8Z, is also highly immunoevasive,
with a 63% reduction compared to wild type. Overall, the global,
quantitative immunoreactivity was found to have a highly
significant and surprisingly close correlation with the predicted
Sepi parameter (linear R2 = 0.64; non-zero slope P,0.0001;
Fig.4E). Thus, Sepi offered reasonable predictive power even for
individual P99bL designs. In total, the algorithm successfully
incorporated compatible and increasingly effective deimmunizing
mutations so as to achieve a systematic reduction in immunogenic
potential.
Discussion
Mutagenic deletion of T cell epitopes, which has been
successfully implemented with diverse proteins, is a powerful
means for deimmunizing biotherapeutics. With very few excep-
tions, however, published studies of T cell epitope deletion, in full
length proteins, have focused on disrupting one or two immuno-
genic regions [9,10,11,12,14,25,43]. Indeed, there is debate
regarding the feasibility of broad, protein-wide epitope deletion,
which is complicated by the high degree of MHC II polymorphism
in human populations [44]. Thus, while there are many reports of
limited but successful T cell epitope deletion, one is left to wonder
how many projects might have failed due to the presence of
numerous and dispersed immunogenic regions that could not be
targeted simultaneously using conventional strategies. To more
fully understand this challenge, we have conducted a combined
computational and experimental analysis of the immunogenicity
and functionality tradeoffs that are inherent to the deimmuniza-
tion problem.
The studies described here were enabled by an advanced
deimmunization algorithm that seamlessly integrates immunogen-
ic epitope prediction with in silico analysis of the functional
consequences associated with deimmunizing mutations. We
combined the IP2 deimmunization formulation with the PEPFR
Fig. 7. Global categorical immunoreactivity for full length protein designs. The binding strength of individual peptides for MHC II alleles
DRB1*0101, 0401, 0701, and 1501 were binned as strong (IC50,1 mM, red), moderate (1 mM#IC50,10 mM, orange), weak (10 mM#IC50,100 mM,
yellow), or non-binding (IC50 $100 mM, not shown). The counts for each enzyme’s constituent peptides were summed and plotted by semi-
quantitative category (y-axis). The horizontal hatched lines are visual guides for the wild type binding counts in each category.
doi:10.1371/journal.pcbi.1003988.g007
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optimization algorithm [28,32] to design a suite of 18 Pareto
optimal P99bL variants. Each of these designs optimally balances
two objective functions – one modeling immunogenicity and the
other functionality – such that no other single variant is predicted
to outperform with respect to both design objectives. Inspection of
the Pareto optimal designs reveals that, in the context of the
mathematical model, there is an inverse relationship wherein ever
greater deimmunization is achieved at the expense of progressively
reduced function (Fig. 8A). To assess the practical implications of
these predicted tradeoffs, we have recombinantly produced all 18
designed enzymes and rigorously characterized their stability,
activity, and immunoreactivity with human MHC II proteins. The
results of this analysis represent the first systematic assessment of
the functional penalty that is paid for pursuing progressively more
deimmunized drug candidates.
Our previous work had demonstrated the capacity to design
P99bL variants bearing 1–5 deimmunizing mutations yet retaining
wild type or better activity and near wild type stability [25,31]. By
more thoroughly mapping the Pareto optimal design space, we
show here that up to seven immunogenic regions can be
simultaneously targeted while incurring essentially no loss in
molecular stability and function (see design 8T, Table 1).
Considering only the most aggressive designs (8T to 8Z), the
computational Pareto curve suggested that there would be an
accelerating loss of molecular function throughout the series,
ultimately resulting in a 6-fold deterioration relative to 8T
(Fig. 8A). The experimental analysis verified the predicted trend,
revealing that the 8-mutation series did in fact exhibit a systematic
reduction in stability and catalytic efficiency. Importantly,
however, design 8Z showed a mere 40% reduction in catalytic
proficiency relative to 8T. This dramatic difference in the
magnitude of DSseq versus measured change in molecular function
suggests a non-linear relationship between the statistical sequence
potential and actual experimental performance. Indeed, a non-
linear correlation is suggested by the above graphical analysis
(Fig. 4A, C, D). Thus, it seems likely that more aggressive designs
exhibiting even higher Sseq penalties might be realized experi-
mentally before reaching the point of diminishing returns. In other
Fig. 8. Comparison of computed and experimental Pareto optimal plots. A Pareto plot of computed design parameters Sseq vs. Sepi. B
Experimental analog of the computed Pareto plot. An integrated score for experimentally measured molecular function (equation 3) is plotted vs. a
global score for experimentally determined immunoreactivity (equation 4). C Experimental Pareto plot of normalized, reciprocal Tm vs. Global
Quantitative Immunoreactivity. D Experimental Pareto plot of normalized Km vs. Global Quantitative Immunoreactivity. E Experimental Pareto plot of
normalized, reciprocal kcat vs. Global Quantitative Immunoreactivity. F Experimental Pareto plot of normalized, reciprocal kcat/Km vs. Global
Quantitative Immunoreactivity. G Experimental Pareto plot of averaged, normalized, reciprocal kcat and Tm vs. Global Quantitative Immunoreactivity.
H Experimental Pareto plot of averaged, normalized, reciprocal kcat/Km and Tm vs. Global Quantitative Immunoreactivity. Pareto optimal enzymes are
shown as blue circular markers, sub-optimal 4-mutation variants are shown as orange circular markers, and wild type P99bL is shown as a red square.
Note that the computed Pareto plot best captures overall molecular performance, as represented by integrated performance values (e.g. averaging
kinetic parameters with thermostability parameters).
doi:10.1371/journal.pcbi.1003988.g008
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words, it appears we have yet to reach the practical limit of epitope
depletion for P99bL.
While the quantified losses in activity and stability were not as
sharp as predicted by the Sseq design parameter, there was in fact a
general trend towards escalating loss of function with more
aggressive deimmunization. To better visualize these real world
tradeoffs, we constructed the experimental analog of the Pareto
curve (Fig. 8B). This analysis entailed plotting an integrated
experimental performance score (averaging the normalized,
reciprocal values for Tm, kcat, and kcat/Km; equation 3) vs. the
quantitative global immunoreactivity score (equation 4). The
graphical analysis clearly shows that more aggressively deimmu-
nized enzymes sustained progressively greater losses of molecular
function. Analogous plots were constructed for various individual
performance parameters as well as alternative combinations of
these parameters (Fig. 8C-H). It is interesting that the computa-
tionally generated Pareto plot most effectively captures the general
trends observed with integrated, as opposed to individual,
experimental performance measures (compare Fig. 8 panels B,
G and H to panels C, D, E and F). This is a notable and
advantageous outcome, as biotherapeutic researchers will typically
be interested in overall molecular performance as opposed to any
single metric (e.g. thermostability, binding affinity, rate accelera-
tion, or catalytic efficiency). As a whole, the parallels between the
computational and experimental Pareto plots are striking, and this
observation underscores the PEPFR algorithm’s capacity to
effectively factor in the inherent tradeoffs between immunogenicity
and molecular function.
As a final note, previous engineering of P99bL with the IP2
algorithm had produced higher activity variants than those
designed with the earlier DP2 algorithm [31]. However, the IP2
designs from the former study were generated after locking down
all residues in close proximity the active site. This raised the
question of whether or not the combined 1-body + 2-body
sequence potential of IP2 was in fact more effective than the 1-
body potential implemented in DP2, where mutations to active site
residues had been allowed [25]. The Pareto optimal designs from
the present study did not benefit from locked active site residues,
yet the 4-mutation and 5-mutation designs from this study
substantially outperformed previous 2-mutation DP2 designs and
were largely equivalent to previous 4-mutation and 5-mutation IP2
designs in which the active site had been held invariant (S3 Fig.).
This result shows that the more advanced sequence potential of
IP2 can in fact generate highly mutated and yet highly active
proteins in the absence of detailed structure-function information.
Moreover, when residues need not be locked down during the
design process, there is greater inherent capacity for epitope
deletion.
In conclusion, we have computationally and experimentally
mapped the deimmunized Pareto frontier of P99bL. The
predictions underlying the design process correlated well with
experimental analyses of protein function. In particular, we
observed that incremental deletion of progressively more T cell
epitopes lead to a relative escalation in concomitant loss of
function. Thus, the predicted tradeoffs underlying protein
deimmunization were borne out in real world analyses. Nonethe-
less, all 18 of the computationally designed enzymes proved to
exhibit reasonable thermostability and impressive activity; not a
single design failed to express or function. The most highly
engineered enzyme, which incorporated eight mutations targeting
seven distinct epitope clusters, was found to have a 39% reduction
in high affinity MHC II binding interactions while maintaining
well over 50% of the wild type enzyme’s catalytic activity. It is
therefore evident that we have additional capacity for designing
even more extensively deimmunized yet functional P99bL
variants. If these trends translate to other therapeutic proteins,
as anticipated, the integrated design algorithms evaluated here will
accelerate identification of engineered variants spanning a broad
spectrum of immunogenic potential and biological function. These
panels of deimmunized proteins should prove a rich resource from




Oligonucleotides for sequencing and standard PCR methods
(25 nmol scale, standard desalting) and oligonucleotides for gene
synthesis (100 nmol scale, PAGE Purified) were purchased from
Integrated DNA Technology (San Diego, CA). Nitrocefin was
purchased from Oxoid (Cambridge, UK). Human lysozyme and
SYPRO Orange 50006Protein Stain were purchased from Sigma
(St. Louis, MO). MicroAmp Fast Optical 0.1 ml 96-Well Plates
and MicroAmp Optical Adhesive Film were from Applied
Biosystems (Bedford, MA). Restriction enzymes and PCR reagents
were purchased from New England BioLabs (Ipswich, MA).
Growth media was purchased from Becton Dickinson (Franklin
Lakes, NJ). Plasmid purification kits and Ni-NTA resin were
purchased from Qiagen (Valencia, CA). PCR cleanup and gel
extraction kits were from Zymo Research (Irvine, CA). Peptides
derived from P99bL were ordered from GenScript (Piscataway,
NJ), and were greater than 85% pure. Biotinylated tracer peptides
were purchased from 21st Century Biochemicals (Marlborough,
MA). MHC II DR molecules were purchased from Benaroya
Research Institute (Seattle, WA), anti-MHC II-DR antibody from
Biolegend (San Diego, CA), and DELFIA Eu-labeled Streptavidin
was from PerkinElmer (Boston, MA). Unless noted, all other
chemicals and reagents were from VWR (Radnor, PA).
Computational Deimmunization
Functionally permissible mutations were identified using an IP2
sequence potential, generated essentially as described [28]. Briefly,
a multiple sequence alignment (MSA) of 94 homologs from Pfam
00144, including the wild type, was constructed by filtering for $
30% sequence identity to wild type, #90% sequence identity to
each other, and #25% gaps. The negative log frequency of each
amino acid a at each position i was used to compute position-
specific one-body terms wi(a). Allowed substitutions were con-
strained to those appearing at or above background amino acid
frequencies [45]. Two-body terms wi,j (a,b) for pairs of amino acids
(a,b) at coupled positions (i,j) were computed as the negative log
amino acid frequency of the pair, minus the corresponding one-
body terms, which avoids double counting. Only pairs of positions
with significant coupling according to a x2-based test were
included in the sequence potential. In addition to mutational
constraints based on the evolutionary sequence record, prolines
and cysteines were neither mutated out of nor substituted into the
engineered enzyme variants.
The impact of functionally acceptable mutations on putative T
cell epitope content was analyzed with the ProPred epitope
predictor set to a 5% threshold. ProPred has been shown to be one
of the most accurate MHC II prediction tools in the public space,
and readers are referred to the following references for a detailed
comparison of different methods [22,46]. The analysis considered
MHC II alleles DRB1*0101, 0401, 0701, and 1501, which are
common alleles [42] and for which binding assays had been fully
optimized [33]. Each nonamer peptide X considered in the
optimization (i.e., incorporating a contiguous combination of wild
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type residues and allowed substitutions) was classified as either a
binder or non-binder of the four target MHC II alleles. The
number of binders was summed to generate the nonamer’s epitope
score e(X). As a comparison, putative epitopes from ProPred
predictions were subsequently analyzed using the IEDB consensus
[22] and NNAlign [34] prediction methods with binding cutoffs
(IEDB 5% or 10%; NNAlign 50 nM or 1000 nM) set to values
commonly used in protein immunogenicity prediction [47].
Ultimately, we found that the alternative epitope predictors, when
applied to the ProPred based designs, yielded the expected trends
of immunogenicity-functionality tradeoffs across the set of 18
P99bL variants (S4 Fig.).
Given a wild-type sequence and a mutational load, PEPFR
identifies each Pareto optimal variant s with the specified number
of mutations making undominated tradeoffs between the compet-
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where bracketed expressions indicate selection of the amino acid at
the position or the substring of amino acids at the contiguous
positions.
Briefly, PEPFR identifies the Pareto frontier of this two-objective
space (Sepi vs. Sseq; see Fig. 2) by employing a divide-and-conquer
algorithm wrapped around an IP2-based variant optimization.
Given a region in the objective space (min/max values for the
objectives), PEPFR uses a constrained version of IP2 to optimize an
undominated design in that region. PEPFR then further divides the
region into four quadrants around the design and recurses only
for the upper-left and lower-right quadrants, as the upper-right is
dominated and the lower-left is empty. It thereby finds all and
only the Pareto optimal designs, and does so efficiently in that the
number of calls to the integer programming optimizer is
proportional to the number of Pareto optimal designs. We used
PEPFR as described for deimmunization (He et al. 2012), with the
underlying integer programming instances optimized by calls to
the IBM CPLEX package.
Cloning, Expression, and Purification
Gene synthesis was performed using a two-step process.
First, an assembly reaction was performed using fifty-two
synthetic oligonucleotides encoding each design with an
appended 59- ompA leader sequence and 39 hexa-His coding
sequence (sequence GGGSAETVEHHHHHH). The assem-
bled genes were then amplified in a second PCR using external
primers. The constructs were then digested using Xba1 and
HindIII, ligated into similarly digested pET26b, and electro-




Expression was performed in 200–500 ml of LB medium
containing 30 mg/ml kanamycin (LB-Kan). Expression cultures,
from a 1:100 subculture of saturated overnight cultures, were
grown with aeration at 37uC in 2 L baffled flasks for an hour and
forty five minutes. The temperature was then shifted to 16uC,
equilibrated for 15 minutes, and expression was induced with
1 mM IPTG. Following 12–20 hours of induction at 16uC,
osmotic shocktates were prepared using the protocol described
in the Epicentre PeriPreps Periplasting Kit with slight modifica-
tions. Briefly, cells were pelleted at 6000g for 10 minutes and
resuspended in PeriPreps Periplasting Buffer containing 1.5 mg/ml
human lysozyme. Cells were quenched after a five minute
incubation period with ice-cold water, and then incubated on ice
for 10 minutes. The periplasmic fraction was collected by spinning
the shocktate at 14,000g for 10 minutes and collecting the
supernatant.
Proteins were purified from clarified periplasmic fraction
using Ni-NTA resin (400 ml bed volume). After the clarified
periplasmic fraction was flowed through the resin by gravity,
the column was washed 2 times with 1 mL of PBS (137 mM
NaCl, 2.6 mM KCl, 10 mM Na2HPO4, 1.7 mM KH2PO4,
pH 7.4) containing 20 mM imidazole, and the enzyme was
eluted with 2 ml of PBS containing 200 mM imidazole. The
elution fraction was either dialyzed (10,000 MW cutoff) against
3 changes of 4 L PBS or concentrated and buffer exchanged by
centrifugation (10,000 MW cutoff) against 3 washes of 15 mL
PBS to a final concentration of 0.5–2 mg/ml protein. Purified
protein was stored at 4uC prior to further analysis. All protein
preparations were.95% pure, as determined by reverse-phase
HPLC analysis (Agilent 1200 Series HPLC) on a Vydac 214TP
180mm C4 column, eluted at 65uC with a gradient of
[90% acetonitrile/9.9% water/0.1% trifluoroacetic acid] in
[99.9% water/0.1% trifluoroacetic acid] at a flow rate of
1 ml/min.
Kinetic Studies
Nitrocefin substrate stock was prepared immediately prior to
the experiments by dissolving nitrocefin powder in DMSO to a
concentration of 20 mM. Triplicate assays were run in 96-well
plate format at 30uC measuring absorbance at 490 nm
(Molecular Devices SpectraMax 190 plate reader). Absorbance
measurements were converted to micromolar product concen-
trations using the appropriate molar absorptivity (eM =
20,500 M21 cm21). The assay buffer was PBS, and each well
contained a final enzyme concentration of 50 ng/ml, 0.04%
BSA, and nitrocefin at concentrations ranging from 10 mM to
200 mM. Initial reaction rates were plotted against substrate
concentration, and Michaelis-Menten kinetic parameters were
determined by nonlinear regression using GraphPad Prism v.5
software (La Jolla, CA). Measurements were made in triplicate,
and enzymes were purified and assayed in biological duplicate.
Thermostability
Differential scanning fluorimetry was performed essentially as
described (Niesen, Berglund et al. 2007) using an ABI 7500 Fast
Real-Time PCR System from Applied Biosystems (Bedford, MA).
Proteins and SYPRO Orange were diluted in PBS. Final protein
concentrations were 100 mg/ml and final dye concentrations were
56. Twenty ml reactions were performed in 12 replicates. The
PCR gradient was run from 25–94uC with a 1 minute equilibra-
tion at each degree centigrade. Fluorescence was quantified using
the preset TAMRA parameters. Melting temperatures were
determined by data analysis with the ‘‘DSF Analysis v3.0.xlsx’’
Excel sheet (ftp://ftp.sgc.ox.ac.uk/pub/biophysics/) and Graph-
Pad Prism v.5 software.
Integrated Molecular Performance:
To construct the experimental equivalent of the Pareto optimal
plot (Fig. 8), a global molecular performance score was calculated
for each individual enzyme using equation 3:
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where ‘‘gT{1m ’’ is the normalized reciprocal Tm value, ‘‘gk-1cat’’ is the
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reciprocal kcat/Km value. This integrated performance score effectively
averages the normalized reciprocal values for thermal stability, rate
acceleration, and catalytic efficiency, yielding the experimental analog
of Sseq.
MHC Binding Assays
MHC II competition binding assays were performed as
described [33]. All data were fit to the one-site log(IC50) model
by non-linear regression in GraphPad Prism v.5 software. Global
immunoreactivity values were computed for each variant by (i)
averaging the IC50 values for all component peptides, (ii)
multiplying this figure by the number of peptides with IC50.
250 mM, (iii) taking the reciprocal of the resulting product, and (iv)
taking the ratio of this computed value for a variant to that of wild













where ‘‘IC50’’ is the mean IC50 value averaged over all
component peptides having affinities ,250 mM, ‘‘#Nonbinders’’
is the total count of component peptides with affinities $250 mM,
and the subscripts ‘‘mut’’ and ‘‘wt’’ indicate calculations for
mutant and wild type proteins, respectively. This calculation
accounted for both the affinity of any quantified binders and the
equally important metric of total count for non-binders.
Statistical Analysis
Linear regressions of experimental performance vs. computa-
tional predictions employed an F test for statistical significance of
non-zero slopes. Significance was determined at the a= 0.05 level.
Supporting Information
S1 Fig Melting Profiles from differential scanning fluorimetry. Raw
fluorescence vs. temperature data from differential scanning fluorim-
etry is shown. Increased fluorescence correlates with protein unfolding,
and Tm is computed as the mid-point of the low to high transition.
Enzyme designs are indicated above each graph. Note that none of the
engineered variants exhibits any measurable unfolding at 37uC.
(TIF)
S2 Fig Local environment of residue R105. The P99bL peptide
backbone (PDB ID 1XX2A) is rendered as a grey ribbon, and
residues of interest are rendered as van der Waals surfaces. Shown
are D86, D87, D108, E300, and in the center R105. Carbon is
colored cyan, nitrogen blue, oxygen red, and hydrogen white. The
cationic residue R105 sits in a pocket lined by the four acidic
residues. Mutation R105S removes the putative stabilizing charge
of R105 and may drive protein destabilization through electro-
static repulsion of the four highlighted acidic residues.
(TIF)
S3 Fig Comparison of current and previous P99bL experi-
mental results. The activity and stability of current Pareto
optimal P99bL designs has been compared with that of earlier
P99bL designs. Values are normalized to the wild type values
from the corresponding article. (A) Km value. (B) kcat value. (C)
kcat/Km value. (D) Apparent Tm value. Left of the vertical
hashed line are designs from the current study. Pareto optimal
enzymes are in dark blue, and sub-optimal enzymes are in
yellow. Right of the vertical hashed line in green is a 2-mutation
enzyme from an earlier experimentally driven deimmunization
program [9], in cyan are 2-mutation enzymes from a previous
paper employing the DP2 algorithm [25], and in light blue are
4- and 5-mutation enzymes from a previous paper employing
the IP2 algorithm [31]. Note that 4 and 5-mutation designs from
the current study exhibit similar performance to the 4 and 5-
mutation designs from the earlier IP2 study, despite the fact that
the active site residues were locked down in the earlier study but
were allowed to mutate here. Additionally, note that the current
Pareto optimal designs generally outperform earlier DP2
designs, despite the substantially higher mutational loads of
most enzymes from the current study.
(TIF)
S4 Fig Predicted sequence scores versus epitope scores using
alternative epitope predictors. The IEDB consensus and NNAlign
epitope prediction methods were applied to the 18 P99bL designs
generated using the ProPred epitope predictor. The expected
tradeoffs between epitope score and sequence score manifest the
same general trends as in Figure 2. (A) NNAlign based
predictions at a 50 nM threshold, (B) IEDB based predictions
at a 5% threshold, (C) NNAlign based predictions at a 1000 nM
threshold, (D) IEDB based predictions at a 10% threshold.
Designs are indicated by name, and wild type is shown as an open
red circle.
(TIF)
S1 Table Performance parameters for R105S point mutant.
(DOCX)
S2 Table Synthetic peptides used in MHC II binding studies.
(DOCX)
S3 Table Various epitope prediction methods and correlation
with experimental binding.
(PDF)
S4 Table IEDB consensus predictions and correlation with
experimental binding.
(PDF)
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